Pharmaceutical producer Novo Nordisk on Wednesday introduced it is going to be providing a direct-to-patient program for uninsured and underinsured people to have the ability to pay money for its weight reduction product Wegovy at a considerably decreased price.
The drugmaker has named its new program NovoCare® Pharmacy, which is able to promote all dose strengths of Wegovy at $499 monthly. In keeping with the corporate, about 90 % most sufferers pay a month-to-month copay of zero to $25 and this new program is geared toward eligible people who find themselves uninsured or are on insurance coverage that do not cowl weight problems medicines.
The listing value for one month’s provide of Wegovy is $1,349.
“NovoCare® Pharmacy expands the company’s toolkit of offerings to meet the diverse needs of people living with obesity,” the corporate stated in a press launch, noting this announcement comes on the heels of the Meals and Drug Administration (FDA) not too long ago confirming that each Wegovy and Ozempic, types of the GLP-1 remedy semaglutide, are now not in scarcity.
Wegovy is a type of semaglutide indicated particularly for weight reduction. One group of insured people who could not have the ability to entry it are Medicare beneficiaries because the federal insurance coverage program remains to be at present prohibited from protecting weight reduction medicine. Medicare enrollees can obtain protection for the remedy whether it is prescribed for its different indication, the decreased danger of cardiovascular dying, coronary heart assault and stroke.
Whereas Wegovy and Ozempic have been each listed on the FDA’s drug scarcity listing, compounding pharmacies have been capable of promote copycat variations of semaglutide at a considerably decreased value. These merchandise weren’t FDA-approved and as such weren’t coated by insurers.
The company’s pointers do present a while for sufferers who have been utilizing compounded medicine to transition to the FDA-approved variations of the medicine and this new program from Novo Nordisk seems to cater to people who have been accustomed to getting semaglutide at a decreased fee with out insurance coverage.
The price of compounded variations of semaglutide offered by on-line telehealth suppliers ranged from $150 to $280 for a month’s provide.
“Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the U.S. have coverage specifically for weight management medicines, and 90% of Wegovy® patients with coverage pay $0 to $25 a month for Wegovy®,” stated Dave Moore, president of Novo Nordisk Inc.
Eli Lilly, the producer of the GLP-1 drug tirzepatide, equally made a transfer final 12 months to supply its in-demand drug at a decreased price by offering an possibility of shopping for it in single-dose vials as a substitute of in autoinjectors.
